Walsh, Leah E. http://orcid.org/0000-0001-7081-0306
Polacek, Laura C. http://orcid.org/0000-0002-7106-0815
Panageas, Katherine
Reiner, Anne http://orcid.org/0000-0002-1258-6112
Walbert, Tobias
Thomas, Alissa A.
Buthorn, Justin
Sigler, Allison
Prigerson, Holly G. http://orcid.org/0000-0002-7075-4268
Applebaum, Allison J.
Diamond, Eli L. http://orcid.org/0000-0001-5456-5961
Funding for this research was provided by:
National Cancer Institute (P30 CA008748, P30 CA008748)
American Society of Clinical Oncology Career Development Award
Article History
Received: 13 March 2022
Accepted: 7 April 2022
First Online: 18 April 2022
Declarations
:
: Dr. Diamond discloses unpaid editorial support from Pfizer, Inc, and paid advisory board membership for Day One Biopharmaceuticals and Springworks Therapeutics, both outside the submitted work. Dr. Applebaum receives support from Bluenote Therapeutics. Dr. Walbert discloses paid advisory board membership for AstraZeneca and work for NovoCure.
: This study was approved by the ethics at each institution (IRB Number 15-034 at Memorial Sloan Kettering Cancer Center; IRB number 17-0540 at University of Vermont, IRB number 11458 at Henry Ford Health System).
: Informed consent was obtained from all individual participants (patients, caregivers, and physicians) included in the study. Consent for publication was obtained via informed consent and all data presented have been de-identified.